XFOR catalyst calendar

X4 Pharmaceuticals, Inc

Upcoming catalysts
2
Cash runway
29.9 months
Cash & investments
$195M
Phase 3 programs
2

X4 Pharmaceuticals, Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 28, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 29.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 11 concluded trials, 73% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 28, 2026 est. Next quarterly earnings (projected) Earnings —
September 15, 2027 A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections Trial Milestone Phase 3

Track XFOR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open XFOR in the tracker

Recent history

DateEventTypePhase
October 8, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
September 9, 2026 8-K filed: Other event Filing —
September 8, 2026 8-K filed: Other event Filing —
July 1, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 13, 2026 8-K/A filed: Leadership change Corporate —
May 12, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function Trial Milestone Phase 1
December 23, 2025 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome Trial Milestone Phase 3
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 27, 2025 8-K filed: Material agreement Corporate —
September 17, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 25, 2025 8-K filed: Leadership change Corporate —
August 13, 2025 8-K filed: Material agreement, Other event Corporate —
August 12, 2025 8-K filed: Material agreement, Leadership change, Other event Corporate —
June 23, 2025 8-K filed: Material agreement Corporate —
May 19, 2025 Drug-Drug Interaction Potential of Mavorixafor Trial Milestone Phase 1
May 1, 2025 Quarterly results filed (8-K) Earnings —
April 24, 2025 8-K filed: Other event Filing —
August 27, 2024 A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Trial Milestone Phase 1/Phase 2
October 31, 2022 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Trial Milestone Phase 1
June 16, 2022 A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome Trial Milestone Phase 2
April 14, 2022 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma Trial Milestone Phase 1/Phase 2
August 8, 2018 Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma Trial Milestone Phase 1/Phase 2
March 15, 2018 X4P-001 and Pembrolizumab in Patients With Advanced Melanoma Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.